Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 June 2026
Eli Lilly's Jaypirca has received a positive CHMP recommendation for the treatment of chronic lymphocytic leukemia (CLL) in the European Union.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
The Committee for Medicinal Products for Human Use (CHMP) met from June 22-25, 2026, resulting in a recommendation for the approval of Eli Lilly's Jaypirca (pirtobrutinib). The drug is intended for adults with chronic lymphocytic leukemia (CLL) across all lines of therapy.
Coverage from Yahoo Finance, GuruFocus, and the European Medicines Agency emphasizes that the marketing authorization application has been submitted to the European Commission. Following these developments, Eli Lilly shares rose over 4%, according to 富途牛牛.
Further developments include the examination of Phase 3 results from the BRUIN CLL-322 trial and exploration of treatment-free remissions with pirtobrutinib, as noted by Oncodaily and Targeted Oncology.
Synthesized by Archynetys from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 1d ago.
Quick answers
What is Jaypirca?
Jaypirca (pirtobrutinib) is a treatment for adults with chronic lymphocytic leukemia (CLL).
Which regulatory body recommended the approval?
The Committee for Medicinal Products for Human Use (CHMP) provided the recommendation.
What was the market reaction for Eli Lilly?
According to 富途牛牛, Eli Lilly and Co (LLY.US) shares rose over 4%.
Coverage (15)
- Eli Lilly Stock Jumps 7% as Medicare Opens GLP-1 Access: What a $2,100 Target Means for Investors TIKR.com · 1d ago
- Eli Lilly Leads 5 Stocks Near Buy Points As The Market Rally Rotates Investor's Business Daily · 1d ago
- Why Is Eli Lilly (LLY) Stock Soaring Today Yahoo Finance · 1d ago
- Lilly Hits Record High Amid Massive Profit Growth, Leads 28 Just Added To Best Stock Lists Investor's Business Daily · 1d ago
- CHMP Recommends Pirtobrutinib for EU Approval in CLL Across All Lines of Therapy OncLive · 1d ago
- Why Is Eli Lilly (LLY) Stock Soaring Today The Globe and Mail · 1d ago
- Pirtobrutinib Plus Venetoclax Shows Promising Results in CLL Oncology News Central · 1d ago
- Eli Lilly shares rise after EU panel backs expanded use of Jaypirca Yahoo Finance · 1d ago
- Matthew Davids' Comments on the New Phase 3 Results From the BRUIN CLL-322 Trial - Dana-Farber Oncodaily · 1d ago
- Eli Lilly (LLY) Gains EMA Support for Cancer and Diabetes Treatm GuruFocus · 1d ago
- Eli Lilly (LLY) Receives Positive EMA Opinion for Jaypirca Treat GuruFocus · 1d ago
- Dr Ahn: Exploring Treatment-Free Remissions With Pirtobrutinib in CLL Targeted Oncology · 1d ago
- U.S. Stocks Move | Eli Lilly and Co (LLY.US) Rises Over 4% as Jaypirca Marketing Authorization Application Submitted to European Commission 富途牛牛 · 1d ago
- Lilly's Jaypirca (pirtobrutinib) recommended by CHMP for approval in the European Union for adults with chronic lymphocytic leukemia (CLL) across all lines of therapy Yahoo Finance · 1d ago
- Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 June 2026 European Medicines Agency (EMA) · 1d ago
Topics
Related trends
European Regulator Calls for Amgen’s Tavneos to Have Authorization Revoked
European regulators are recommending the revocation of marketing authorization for Amgen's autoimmune disease drug, Tavneos.
Sangamo to put ‘substantially all’ assets for sale in bankruptcy, lines up Lilly and Astellas as buyers
Sangamo Therapeutics' bankruptcy filing and asset sale to Lilly and Astellas is making waves in the biotech industry.
Trump may be mystery patient in odd case of 79yo getting experimental obesity drug
Speculation swirls around a 79-year-old patient who received an experimental weight loss drug, with former President Trump as the suspected recipient.